USPTO serial 77543711
ORAMELT
Reviewed by CopyMark Law Group
Reg. 4247772Status 710
- Filing date
- Status date
- Registration date
- Nov 27, 2012
- Examiner
- HSU, FONG
- Law office
- TMO LAW OFFICE 129 - EXAMINING ATTORNEY ASSIGNED
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with ORAMELT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
DUBLIN, IE
Biovail Laboratories International SRL
Christ Church, BB
Other trademarks owned by Biovail Laboratories International SRL
VALEANT PHARMACEUTICALS IRELAND LIMITED
DUBLIN, IE
Other trademarks owned by VALEANT PHARMACEUTICALS IRELAND LIMITED
Valeant International (Barbados) SRL
Christ Church, BB
Other trademarks owned by Valeant International (Barbados) SRL
VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L
LUXEMBOURG CITY, LU
Other trademarks owned by VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L
Valeant International (Barbados) SRL
Christ Church, BB
Other trademarks owned by Valeant International (Barbados) SRL
Hamilton, BM
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Robert J. Gorman
1400 N. Goodman StreetLaw DepartmentRochester, NY 14609Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the central nervous system; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Parkinson's disease; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Huntington's disease; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of amyotrophic lateral sclerosis; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Alzheimer's disease; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of epilepsy; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the treatment of depression, depressive disorders and mental illnesses; antidepressants; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of anxiety; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of pain; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the cardiovascular system; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of cardiopulmonary disorders, diseases, conditions, and ailments; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of hypertension, angina, high blood pressure, heart failure and ventricular dysfunction; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of metabolic disorders, diseases, conditions, and ailments; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of diabetes; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of viral and infectious diseases; Drug delivery agents consisting of rapidly dissolving compounds, formulations, compositions and agents that facilitate delivery of a wide range of human and veterinary pharmaceuticals; and Drug delivery agents in the nature of pill coatings that facilitate delivery of a wide range of human and veterinary pharmaceuticals; Pharmaceutical preparations and substances for the prevention, treatment, and alleviation of Tourette syndrome | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BAUSCH HEALTH IRELAND LIMITED
- Other trademarks owned by Biovail Laboratories International SRL
- Other trademarks owned by VALEANT PHARMACEUTICALS IRELAND LIMITED
- Other trademarks owned by Valeant International (Barbados) SRL
- Other trademarks owned by VALEANT PHARMACEUTICALS LUXEMBOURG S.À.R.L
- Other trademarks owned by Valeant International (Barbados) SRL
- Other trademarks owned by VALEANT INTERNATIONAL BERMUDA
- Other trademarks in Class 005
- Similar marks named ORAMELT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 18, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 18, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 18, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 18, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 18, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 18, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 18, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 18, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 11, 2026 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Apr 16, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 28, 2019 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Mar 20, 2019 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 16, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 16, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 21, 2018 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 27, 2017 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 11, 2017 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Mar 3, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 21, 2015 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jan 22, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 16, 2013 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Mar 16, 2013 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 25, 2013 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Nov 27, 2012 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 11, 2012 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 11, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 22, 2012 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 10, 2012 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Aug 1, 2012 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Aug 1, 2012 | ATRQ | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | — |
| Aug 1, 2012 | ADBS | 1(B) BASIS DELETED; NEW BASIS REQUESTED | — |
| Jul 31, 2012 | 44EG | 44(e) PETITION - GRANTED | — |
| Jul 27, 2012 | ERTI | TEAS RESPONSE TO PETITION INQUIRY LETTER | — |
| Jul 3, 2012 | PILM | PETITION INQUIRY LETTER ISSUED | — |
| Jul 2, 2012 | APET | ASSIGNED TO PETITION STAFF | — |
| Jun 26, 2012 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jun 26, 2012 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Jun 6, 2012 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 5, 2012 | EX4G | SOU EXTENSION 4 GRANTED | — |
| May 31, 2012 | EXT4 | SOU EXTENSION 4 FILED | — |
| May 31, 2012 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 6, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 5, 2011 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 1, 2011 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 1, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 7, 2011 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 6, 2011 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 6, 2011 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 1, 2011 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 1, 2011 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 6, 2011 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Mar 23, 2011 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Nov 19, 2010 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 17, 2010 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 17, 2010 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 17, 2010 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 13, 2010 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 1, 2010 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 6, 2010 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 6, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 26, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 20, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 27, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 27, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 27, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 29, 2009 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 29, 2009 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 29, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 7, 2009 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 7, 2009 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 7, 2009 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 17, 2009 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 4, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 4, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 4, 2009 | ALIE | ASSIGNED TO LIE | — |
| Jun 3, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2009 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 22, 2009 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 5, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 5, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 5, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 19, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 14, 2008 | NWAP | NEW APPLICATION ENTERED | — |